KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

TherapeuticsMD (TXMD) FCF Margin (2016 - 2025)

Historic FCF Margin for TherapeuticsMD (TXMD) over the last 16 years, with Q3 2025 value amounting to 127.42%.

  • TherapeuticsMD's FCF Margin rose 1404000.0% to 127.42% in Q3 2025 from the same period last year, while for Sep 2025 it was 74.96%, marking a year-over-year increase of 3135000.0%. This contributed to the annual value of 66.44% for FY2024, which is 18391700.0% up from last year.
  • Per TherapeuticsMD's latest filing, its FCF Margin stood at 127.42% for Q3 2025, which was up 1404000.0% from 40.02% recorded in Q2 2025.
  • TherapeuticsMD's 5-year FCF Margin high stood at 5004.52% for Q3 2022, and its period low was 11373.58% during Q3 2023.
  • In the last 5 years, TherapeuticsMD's FCF Margin had a median value of 73.16% in 2024 and averaged 948.75%.
  • Per our database at Business Quant, TherapeuticsMD's FCF Margin crashed by -163781000bps in 2023 and then surged by 113606100bps in 2024.
  • TherapeuticsMD's FCF Margin (Quarter) stood at 257.0% in 2021, then tumbled by -83bps to 44.1% in 2022, then crashed by -2341bps to 988.05% in 2023, then skyrocketed by 100bps to 2.55% in 2024, then skyrocketed by 4899bps to 127.42% in 2025.
  • Its last three reported values are 127.42% in Q3 2025, 40.02% for Q2 2025, and 177.86% during Q1 2025.